Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
|Slideshows|April 28, 2021
Top Treatment Modalities for Depression
Author(s)John J. Miller, MD
The psychiatrist's armamentarium to treat depression holds promise with a growing arsenal of integrative and pharmacologic options.
Advertisement
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
2
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
3
Presenting Our November 2026 Theme: Emergency Psychiatry
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5